Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis
- PMID: 9168977
- DOI: 10.1006/bbrc.1997.6603
Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis
Abstract
A factor which inhibits osteoclast-like cell formation was found in the conditioned medium of human embryonic lung fibroblasts, IMR-90. The factor, termed osteoclastogenesis inhibitory factor, OCIF, was purified to homogeneity. OCIF is a heparin-binding basic glycoprotein and has been isolated as a monomer with an apparent molecular weight (Mr) of 60,000 and a homodimer with a Mr of 120,000. The N-terminus of OCIF is blocked and the determination of internal amino acid sequences revealed that OCIF has no homology to known proteins. OCIF inhibited in a dose-dependent manner osteoclastogenesis elicited through three distinct signaling pathways stimulated by 1 alpha,25-dihydroxy vitamin D3, parathyroid hormone, and interleukin-11, respectively, in a dose range of 1 to 40 ng/ml (IC50 = 4 to 6 ng/ml). OCIF neither inhibits bone resorption by mature osteoclasts nor exerts any other biological activities. These data strongly suggest that OCIF is a novel cytokine which specifically inhibits osteoclastogenesis.
Similar articles
-
[Osteoclastogenesis inhibitory factor (OCIF)/OPG].Nihon Rinsho. 1998 Jun;56(6):1435-9. Nihon Rinsho. 1998. PMID: 9648461 Review. Japanese.
-
Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone.Biochem Biophys Res Commun. 1998 May 19;246(2):337-41. doi: 10.1006/bbrc.1998.8610. Biochem Biophys Res Commun. 1998. PMID: 9610359
-
Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro.Endocrinology. 1998 Mar;139(3):1329-37. doi: 10.1210/endo.139.3.5837. Endocrinology. 1998. PMID: 9492069
-
Osteoclastogenesis inhibitory factor (OCIF) directly inhibits bone-resorbing activity of isolated mature osteoclasts.Biochem Biophys Res Commun. 1998 Oct 29;251(3):796-801. doi: 10.1006/bbrc.1998.9523. Biochem Biophys Res Commun. 1998. PMID: 9790989
-
The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption.J Bone Miner Res. 2000 Jan;15(1):2-12. doi: 10.1359/jbmr.2000.15.1.2. J Bone Miner Res. 2000. PMID: 10646108 Review.
Cited by
-
Osteoprotegerin rich tumor microenvironment: implications in breast cancer.Oncotarget. 2016 Jul 5;7(27):42777-42791. doi: 10.18632/oncotarget.8658. Oncotarget. 2016. PMID: 27072583 Free PMC article. Review.
-
Mechanosignaling in bone health, trauma and inflammation.Antioxid Redox Signal. 2014 Feb 20;20(6):970-85. doi: 10.1089/ars.2013.5467. Epub 2013 Aug 12. Antioxid Redox Signal. 2014. PMID: 23815527 Free PMC article. Review.
-
Breaking down bone: new insight into site-specific mechanisms of breast cancer osteolysis mediated by metalloproteinases.Genes Dev. 2009 Sep 15;23(18):2117-23. doi: 10.1101/gad.1854909. Genes Dev. 2009. PMID: 19759260 Free PMC article.
-
Association of serum osteoprotegerin with left ventricular mass in African American adults with hypertension.Am J Hypertens. 2010 Jul;23(7):767-74. doi: 10.1038/ajh.2010.59. Epub 2010 Mar 25. Am J Hypertens. 2010. PMID: 20339356 Free PMC article.
-
The role of osteoprotegerin (OPG) receptor activator for nuclear factor kappaB ligand (RANKL) in cardiovascular pathology - a review.Wien Med Wochenschr. 2011 Dec;161(23-24):565-70. doi: 10.1007/s10354-011-0022-7. Epub 2011 Sep 2. Wien Med Wochenschr. 2011. PMID: 21870142 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials